Gyre Therapeutics, Inc.
GYRE Nasdaq
SEC CIK 1124105
Follow Gyre Therapeutics
Weekly email: filings, results
Revenue, last quarter
$32.9M
+0.7% vs same quarter last year
Net income
−$2.5M
−228.6% vs same quarter last year
EPS, diluted
−$0.04
−500% vs same quarter last year
Operating cash flow
−$4M
−54.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $116.6M | $9.9M |
| FY24 | $105.8M | $17.9M |
| FY23 | $113.5M | −$85.5M |
| FY22 | $102.3M | $4.3M |
| FY21 | $7.3M | −$87.9M |
| FY20 | $20.9M | −$56.2M |
| FY19 | - | −$55.2M |
| FY18 | $6K | −$30.1M |
| FY17 | $1M | −$21.6M |
| FY16 | - | −$16.9M |
| FY15 | - | −$14.8M |
| FY14 | $275K | −$6.6M |
| FY13 | $3.6M | −$10M |
| FY12 | $57.9M | −$7M |
| FY11 | $97.6M | −$8.5M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 95.4% | 9.9% | 8.5% |
| FY24 | 96.3% | 15.3% | 16.9% |
| FY23 | 95.9% | −59.3% | −75.3% |
| FY22 | 95.3% | 9% | 4.2% |
| FY21 | - | −1197.8% | −1198.3% |
| FY20 | - | −273.9% | −268.5% |
| FY19 | - | - | - |
| FY18 | - | −563700% | −500916.7% |
| FY17 | - | −2143.6% | −2118% |
| FY16 | - | - | - |
| FY15 | - | - | - |
| FY14 | - | −2730.5% | −2404.7% |
| FY13 | - | −278.9% | −274.6% |
| FY12 | - | −14.1% | −12.1% |
| FY11 | - | −10% | −8.7% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$180K |
| FY24 | −$6M |
| FY23 | $17.4M |
| FY22 | $5.7M |
| FY21 | −$84.6M |
| FY20 | - |
| FY19 | −$43.7M |
| FY18 | −$28.9M |
| FY17 | −$20M |
| FY16 | −$18.9M |
| FY15 | −$19.4M |
| FY14 | −$6.4M |
| FY13 | −$40.7M |
| FY12 | −$64.6M |
| FY11 | −$85.1M |
- Gyre Therapeutics
- Healthcare median
Show the numbers
| Year | Gyre Therapeutics | Healthcare median |
|---|---|---|
| FY25 | 8.5% | −30.6% |
| FY24 | 16.9% | −47% |
| FY23 | −75.3% | −58% |
| FY22 | 4.2% | −80.4% |
| FY21 | −1198.3% | −71.8% |
| FY20 | −268.5% | −62.2% |
| FY19 | - | −46.2% |
| FY18 | −500916.7% | −49.6% |
| FY17 | −2118% | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | −2404.7% | −35.5% |
| FY13 | −274.6% | −37.1% |
| FY12 | −12.1% | −29.1% |
| FY11 | −8.7% | −27.9% |